Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio
July 06 2023 - 7:30AM
Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq:
BWV), a biotechnology and pharmaceutical company focused on
developing and commercializing transformational therapies to
address significant health challenges globally, today announced the
signing of a Master Services Agreement with bfw Advertising Inc.
(“bfw”) to generate marketing and advertising material for Blue
Water’s commercial stage drug portfolio.
Based in Boca Raton, Florida, bfw has more than
three decades of experience supporting clinical and commercial
stage life science companies, generating effective and impactful
brand campaigns, including digital, direct to consumer, and health
care provider content. Bfw will work with Blue Water’s commercial
team to increase awareness for its commercial products through
patient-facing materials, website updates, social ads, targeted
provider engagement, as well as materials to support Blue Water’s
sales team, among other services.
“Signing this agreement and generating an action
plan with bfw is a critical step in the execution of our commercial
launch strategy for our products,” said Joseph Hernandez, Chairman
and Chief Executive Officer of Blue Water. “By creating targeted,
effective marketing materials, we can maximize patient, healthcare
provider, and payor awareness to ensure long-term success for Blue
Water. With their impressive history of campaigns in the life
science industry, we are confident that bfw is the right firm for
this endeavor, and we look forward to the official launches of
these programs in the coming months.”
“With their recent acquisitions and shift into a
commercial-stage as well as clinical-stage company, this is
certainly an exciting time for the team at Blue Water,” said
Christian Boswell, President and Creative Director at bfw. “Through
decades of working in the life science industry, we understand the
intricacies of marketing and advertising in this space and how
challenging it can be for pharmaceutical companies to create
cohesive brands. Blue Water has built a strong portfolio of
products in recent months, and we are honored to utilize our
institutional knowledge to support them and to help them navigate
the commercial arena.”
Blue Water recently expanded its operations to
become a commercial stage company with the acquisition of several
FDA approved assets across multiple indications, including urology,
cardiology, inner ear infections and pain management. Blue Water’s
commercial team will work closely with BFW to identify key areas
where targeted advertising and marketing support can enhance
product uptake and utilization in each respective market.
About Blue Water
Biotech
Blue Water Biotech, Inc. is a biotechnology and
pharmaceutical company focused on developing and commercializing
transformational therapies to address significant health challenges
globally. Headquartered in Cincinnati, OH, the Company owns
ENTADFI®, an FDA-approved, once daily pill that combines
finasteride and tadalafil for the treatment of benign prostatic
hyperplasia. This combination allows men to receive treatment for
their symptoms of benign prostatic hyperplasia without the negative
sexual side effects typically seen in patients on finasteride
alone. The Company also has a robust vaccine pipeline. Blue Water
holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children’s Hospital Medical
Center, St. Jude Children’s Hospital, and The University of Texas
Health Science Center at San Antonio. Blue Water is developing a
Streptococcus pneumoniae vaccine candidate, designed to
specifically prevent highly infectious middle ear infections, known
as AOM, in children, and prevention of pneumonia in the elderly.
The Company is also developing a universal flu vaccine that will
provide protection from all virulent strains in addition to
licensing a novel norovirus S&P nanoparticle versatile
virus-like particle vaccine platform from Cincinnati Children’s to
develop vaccines for multiple infectious diseases, including
Marburg and monkeypox, among others. Additionally, the Company is
developing a Chlamydia vaccine candidate with UT Health Science
Center San Antonio to prevent infection and reduce the need for
antibiotic treatment associated with contracting Chlamydia disease.
For more information about Blue Water, visit www.bwbioinc.com.
About BFW Advertising
Bfw is a full-service integrated branding and
communications agency with a strong grounding in healthcare and
pharma, supporting both clinical and commercial stage companies.
Bfw has worked across a broad range of brands and therapeutic
areas, including men’s and women’s health, CNS, pediatrics,
oncology, pain management, pulmonary and HIV-associated disorders,
as well as leading recruiting campaigns for clinical trial
participants.
Cautionary Note Regarding
Forward-Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements (including, without
limitation, the anticipated benefits of the Company’s agreement
with BFW and the Company’s sales and marketing efforts as described
herein) are based on Blue Water’s current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, risks related to Blue Water’s ability to realize
the benefits of its acquisitions of ENTADFI®, ZONTIVITY®, OTOVEL®,
CETRAXAL®, CONJUPRI®, TREZIX™ and NALFON®; risks related to Blue
Water’s ability to expand its business scope, commercialize
ENTADFI® and integrate the assets and commercial operations being
acquired from WraSer into Blue Water’s business; risks related to
Blue Water’s ability to attract, hire and retain skilled personnel
and establish an effective sales team; risks related to Blue
Water’s ability to enter into a definitive agreement with IQVIA and
optimize its collaboration with IQVIA; risks related to the
development of Blue Water’s vaccine candidates; the failure to
obtain FDA clearances or approvals and noncompliance with FDA
regulations;; risks related to the timing and progress of clinical
development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payor reimbursement;
limited research and development efforts and dependence upon third
parties; and substantial competition. As with any commercial-stage
pharmaceutical product or any product candidate under clinical
development, there are significant risks in the development,
regulatory approval and commercialization of pharmaceutical
products. Blue Water does not undertake an obligation to update or
revise any forward-looking statement. Investors should read the
risk factors set forth in Blue Water’s Annual Report on Form 10-K,
filed with the Securities and Exchange Commission (the “SEC”) on
March 9, 2023 and periodic reports filed with the SEC on or after
the date thereof. All of Blue Water’s forward-looking statements
are expressly qualified by all such risk factors and other
cautionary statements. The information set forth herein speaks only
as of the date thereof.
Media Contact Information:Blue Water Media
RelationsTelephone: (646) 942-5591 Email:
Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bwbioinc.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2023 to Jul 2024